drugset / Trial / NCT01260922
10 mg Donepezil Hydrochloride Orally Disintegrating Tablets Under Fasting Conditions.
RandomizedCrossoverSingle-blind
Summary
This study investigated the relative bioavailability (rate and extent of absorption) of Donepezil Hydrochloride Orally Disintegrating Tablets, 10 mg by Teva Pharmaceuticals, USA with that of Aricept® Orally Disintegrating Tablets, Manufactured and Marketed by Eisai Inc., following a single oral dose (1 x 10 mg orally disintegrating tablet) in healthy adult subjects administered under fasting conditions.
Timeline
- Start
- 2006-04
- Primary completion
- 2006-05
- Completion
- 2006-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Donepezil | Small molecule | 10 mg | Oral |
Indications
No indication recorded.